Effectiveness of "Medisinstart"

Apokus AS

Status: Completed

Conditions: Cardiovascular Diseases

Treatments: Other: Medisinstart

Study type: Interventional

Funder types: Other

Identifiers

NCT02261402

Apokus-001

Details and patient eligibility

About

"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.

The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.

Enrollment: 1,480 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

First time prescription for a drug belonging to one of the following groups (ATC-code):

• Dabigatran etexilate (B01AE07)
• Rivaroxaban (B01AF01)
• Apixaban (B01AF02)
• Beta blocking agents (C07)
• Calcium channel blockers (C08)
• Agents acting on the renin-angiotensin system (C09)
• HMG CoA reductase inhibitors (statins) (C10AA)

Exclusion criteria

• Prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,480 participants in 2 patient groups

Medisinstart

Experimental group

Description:

Patients in this arm will receive the service; Medisinstart

Treatment:

Other: Medisinstart

Current Practice

No Intervention group

Description:

Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.